Atai Life Sciences Nv (ATAI)
$1.75
Insights on Atai Life Sciences Nv
Decreasing Revenue
Revenue is down for the last 2 quarters, 39.0K → 37.0K (in $), with an average decrease of 5.1% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -45.01M → -32.99M (in $), with an average increase of 36.4% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 41.8% return, outperforming this stock by 88.6%
Performance
- $1.75$1.83$1.75
0.0%
Downside
Day's Volatility :4.33%
Upside
4.33%
- $1.14$4.96$1.75
34.86%
Downside
52 Weeks Volatility :77.02%
Upside
64.72%
Returns
| Period | Atai Life Sciences Nv | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 34.59% | 5.1% | -0.2% |
6 Months | -43.18% | -5.5% | -1.5% |
1 Year | -46.81% | 3.9% | -1.7% |
3 Years | -90.8% | 27.0% | 20.6% |
Highlights
Market Capitalization | 290.5M |
Book Value | $1.43 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -1.05 |
Wall Street Target Price | 13.15 |
Profit Margin | 0.0% |
Operating Margin TTM | -52222.97% |
Return On Assets TTM | -26.53% |
Return On Equity TTM | -51.84% |
Revenue TTM | 270.0K |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -83.5% |
Gross Profit TTM | 233.0K |
EBITDA | -140.8M |
Diluted Eps TTM | -1.05 |
Quarterly Earnings Growth YOY | -0.97 |
EPS Estimate Current Year | -0.86 |
EPS Estimate Next Year | -0.9 |
EPS Estimate Current Quarter | -0.21 |
EPS Estimate Next Quarter | -0.22 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 651.43%
Technicals Summary
Sell
Neutral
Buy
Atai Life Sciences Nv is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Atai Life Sciences Nv | -12.5% | -43.18% | -46.81% | -90.8% | -91.0% |
 Moderna, Inc. | -5.8% | -25.37% | -3.05% | 105.16% | 562.58% |
 Regeneron Pharmaceuticals, Inc. | -0.38% | 0.57% | 30.59% | 23.1% | 139.38% |
 Novo Nordisk A/s | -6.71% | 21.75% | 41.76% | 137.45% | 252.55% |
 Seagen, Inc. | -1.72% | 49.08% | 41.0% | 25.43% | 194.5% |
 Vertex Pharmaceuticals Incorporated | -4.66% | 6.21% | 30.93% | 21.64% | 124.53% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Atai Life Sciences Nv | NA | NA | NA | -0.86 | -0.52 | -0.27 | 0.0 | 1.43 |
Moderna, Inc. | 10.82 | 10.82 | 0.0 | -1.63 | 0.27 | 0.12 | 0.0 | 49.12 |
Regeneron Pharmaceuticals, Inc. | 20.46 | 20.46 | 9.01 | 41.59 | 0.19 | 0.1 | 0.0 | 219.38 |
Novo Nordisk A/s | 44.45 | 44.45 | 2.03 | 4.98 | 83.5 | 0.23 | 0.01 | 4.44 |
Seagen, Inc. | NA | NA | 18.53 | -2.89 | -0.23 | -0.12 | 0.0 | 14.54 |
Vertex Pharmaceuticals Incorporated | 25.51 | 25.51 | 0.41 | 14.57 | 0.26 | 0.17 | 0.0 | 56.05 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Atai Life Sciences Nv | Buy | $290.5M | -91.0% | NA | 0.0% |
Moderna, Inc. | Buy | $47.6B | 562.58% | 10.82 | 31.77% |
Regeneron Pharmaceuticals, Inc. | Buy | $82.3B | 139.38% | 20.46 | 33.81% |
Novo Nordisk A/s | Buy | $1.9T | 252.55% | 44.45 | 32.47% |
Seagen, Inc. | Hold | $36.5B | 194.5% | NA | -31.55% |
Vertex Pharmaceuticals Incorporated | Buy | $85.1B | 124.53% | 25.51 | 35.4% |
Institutional Holdings
Morgan Stanley - Brokerage Accounts
1.41%BlackRock Inc
1.16%Suvretta Capital Management, LLC
0.99%HPM Partners LLC
0.81%Two Sigma Investments LLC
0.59%Newtyn Management LLC
0.58%
Corporate Announcements
Atai Life Sciences Nv Earnings
Atai Life Sciences Nv’s price-to-earnings ratio stands at None
Read More
Company Information
who we are: atai is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering from mental health disorders. our mission: we are committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space. our approach: by pooling expertise, best practices, and resources across our entire portfolio, we mitigate risk and responsibly accelerate the development of impactful and evidence-based treatments.
Organization | Atai Life Sciences Nv |
Employees | 133 |
CEO | Mr. Christian Angermayer |
Industry | Commercial Services |
Discover More
Smart For Life Inc
$1.14
-2.56%
Paysign, Inc.
$2.64
+2.33%
Novavax, Inc.
$7.47
-2.86%
Silvercrest Metals Inc
$6.27
-2.18%
Fidelity U.s. Multifactor Etf
$25.43
-0.04%
Proshares Ultrapro Dow30 Etf
$57.69
+0.47%
Invesco Dynamic Large Cap Va
$45.62
-0.02%
Blackrock Municipal Income Quality Trust
$11.15
+0.18%
Tupperware Brands Corporation
$0.86
+0.83%